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candesartan and renal protection: 
more than blocking angiotensin 
type 1 receptor?
Daniela Macconi1 and Giuseppe Remuzzi1,2
Chen et al. show that candesartan (Cand) displays an antioxidant 
action independent of angiotensin type 1 receptor (AT1R) blockade 
that translates into a superior renoprotection of chronic renal 
inflammation. The peculiarity of Cand in combining AT1R-blocking 
activity and an antioxidant action could have important theoretical 
implications for therapy.
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Reactive oxygen species (ROS) comprise a 
series of oxygen intermediates, free radicals, 
and peroxides, produced as by-products 
of oxidative metabolism. The key initial 
step in ROS formation is the conversion 
of molecular oxygen to superoxide (O2•–), 
mainly by the electron transport chain in 
mitochondria and by nicotinamide ade-
nine dinucleotide phosphate (NAD(P)H) 
oxidase (Nox) in membrane. Originally 
discovered in phagocytes, NAD(P)H oxi-
dase is an enzymatic complex formed by 
several subunits: the membrane-associated 
proteins Nox2 and p22phox; the cytosolic 
regulatory proteins p47phox, p67phox, and 
p40phox; and the GTPase Rac1. All compo-
nents of the phagocytic NAD(P)H oxidase, 
as well as two of six proteins homologous to 
the phagocytic Nox2—Nox1 and Nox4—
are expressed in several cells of the kidney, 
including glomeruli (mesangial cells and 
podocytes) and tubules.1 ROS have been 
suggested to mediate both hemodynamic 
and nonhemodynamic actions of angi-
otensin II (Ang II), which plays a causal role 
in renal disease progression. Ang II acti-
vates renal cortical p22phox via angiotensin 
type 1 receptor (AT1R) but downregulates 
p22phox via AT2R.1 Ang II-induced ROS 
can promote endothelial dysfunction, lead-
ing to increased renal vascular resistance.1 
Importantly, ROS can function as second 
messengers for several transcription fac-
tors, including nuclear factor-κB (NF-κB), 
which activates several genes and their 
transcripts involved in renal inflamma-
tion and scarring.1 In this respect, Ang II 
acts as a stimulus of renal hypertrophy and 
extracellular matrix production.1
Chen et al.2 (this issue) have now docu-
mented that the AT1R antagonist cande-
sartan (Cand) displays anti-inflammatory 
properties through a direct antioxidant 
action independent of AT1R blockade. 
By in vitro studies using proximal tubu-
lar epithelial cells, they showed that Cand 
suppresses NF-κB-dependent chemokine 
expression induced by tumor necrosis 
factor-α, an effect that also persists after 
knockdown of AT1R (Figure 1). The mech-
anism underlying the anti-inflammatory 
effect is linked to Cand’s ability to inhibit 
ROS production and to correct the redox 
imbalance (the glutathione/glutathione 
disulfide (GSH/GSSG) ratio) induced by 
tumor necrosis factor-α or, in a similar 
manner, by hydrogen peroxide (H2O2). 
Like other ROS scavengers, N-acetyl-l-
cysteine and pyrrolidine dithiocarbamate, 
Cand exerts a direct antioxidant effect that 
is preserved in cells either transfected with 
a specific AT1R small interfering RNA or 
lacking the receptor and, importantly, is 
not shared by other angiotensin receptor 
blockers (ARBs). Additional properties 
that are unrelated to renin–angiotensin 
system (RAS) blockade have been pre-
viously discovered for another AT1R 
antagonist, telmisartan, that functions as a 
selective peroxisome proliferator-activated 
receptor-γ (PPARγ) modulator.3 Unlike 
telmisartan, Cand has a weak agonizing 
PPARγ activity.3 The finding of Chen et al.2 
that GW9662, a selective PPARγ antagonist, 
did not affect ROS inhibition induced by 
Cand rules out PPARγ as potential media-
tor of Cand’s antioxidant action. Thus, the 
antioxidant effect represents a new effect 
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of AT1R antagonists nonspecific to RAS 
blockade that could have important theo-
retical implications for therapy. Cand might 
target ROS-mediated renal inflammation 
triggered by toxic insults besides Ang II. 
In this context, a functional link was found 
between protein overload-induced ROS 
generation and NF-κB activation in renal 
tubular cells.4 Albumin and IgG elicit rapid 
generation of H2O2 via protein kinase C, 
leading to the upregulation of the NF-κB-
dependent monocyte chemoattractant 
protein-1 (MCP-1) gene. Both NAD(P)H 
oxidase and electron transport chain in 
mitochondria are the enzymatic source 
of ROS.4 Consistently, in experimental 
chronic proteinuric nephropathies, excess 
uptake of plasma proteins in proximal 
tubular cells results in the upregulation of 
chemokines, including MCP-1, responsible 
for the recruitment of inflammatory cells 
into renal interstitium. RAS inhibition, by 
angiotensin-converting enzyme (ACE) 
inhibitors or ARBs, efficiently controls 
both interstitial inflammation and chronic 
disease progression. However, induc-
tion of protein overload proteinuria in 
AT1AR-null mice allowed demonstration 
that targeted deletion of the major isoform 
of murine AT1R does not protect animals 
from tubulointerstitial injury, indicating 
that disease can worsen even in the absence 
of AT1R.5 ROS, besides being common 
messengers for various NF-κB-activating 
signals, including plasma proteins, can 
cause massive, reversible proteinuria and 
a size-selectivity defect of the glomerular 
barrier without apparent ultrastructural 
abnormalities.6 Thus, Cand, by combining 
AT1R-blocking activity and an antioxidant 
action, might provide full protection as 
compared with other ARBs. This would 
be advantageous in cases of ACE inhibition 
resistance. RAS activation can also occur 
as a secondary event due to increased ROS 
generation induced by a primary insult.7 
In this case the simultaneous block of ROS 
generation by Cand would add beneficial 
effects to those achievable by the blocking 
of AT1R alone.
To address whether Cand acts as an anti-
oxidant to the kidney in vivo, Chen et al.2 
investigated the effect of supra-standard 
doses of the AT1R blocker in spontane-
ously hypertensive rats (SHRs), a genetic 
model of essential hypertension. SHRs are 
born normotensive and develop hyper-
tension later in life. The oxidative stress, 
already present in the kidneys of pre-
hypertensive SHRs, is a key determinant 
of the development and the maintenance 
of hypertension. This is supported by the 
evidence that lifelong supplementation of 
antioxidant-rich diet to pregnant SHRs and 
their offspring delays the onset and reduces 
the severity of hypertension.8 Consistently, 
short-term administration of antioxi-
dants is also beneficial for hypertension.9 
Enhanced expression and activation of the 
subunits of the NAD(P)H oxidase complex 
indicate this enzyme as a primary source 
of the oxygen radical O2•–.8,10 A parallel 
increase in kidney nitrotyrosine in SHRs 
reflects production of reactive nitrogen 
species derived by the interaction between 
O2•– and nitric oxide (NO) with conse-
quent reduction in NO bioavailability.8 
The evidence that bioinactivation of NO by 
O2•– in the kidneys of SHRs can be blunted 
by AT1R antagonists, such as Cand, sug-
gests that Ang II can contribute to oxidative 
stress in this model.10,11 Increased oxygen 
radical production by uncoupled NOS, as 
Figure 1 | candesartan (cand) downregulates nuclear factor-κB (nF-κB)-dependent genes 
through a direct antioxidant action independent of AT1R blockade. Tumor necrosis factor-α 
(TNF-α) triggers ROS generation by proximal tubular cells that leads to NF-κB activation and 
upregulation of monocyte chemoattractant protein-1 (MCP-1) and RANTES. On the basis of the 
article by Chen et al.,2 Cand acts as an antioxidant by inhibiting ROS production and by correcting 
the redox imbalance (glutathione/glutathione disulfide ratio) induced by TNF-α. This effect 
is instrumental for the inhibition of the redox-sensitive NF-κB and downregulation of NF-κB-
dependent chemokines. Cand’s antioxidant effect still persists after knockdown of the AT1R by 
transfection of the proximal tubular cell with a specific AT1R small interfering RNA (siRNA). Other 
abbreviations: dsRNA, double-stranded RNA; Gpx, glutathione peroxidase; GSH, glutathione; GSSG, 
glutathione disulfide; H2O2, hydrogen peroxide; IκB, inhibitor-binding protein-κB; IKK, IκB kinase; 
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documented in aortae from young pre-
hypertensive animals, could be another 
potential source of increased renal oxida-
tive stress in SHRs. Concommitant loss 
of antioxidant defense, the inability to 
counter balance increased ROS produc-
tion, to sustains enhanced oxidant stress 
in SHRs.10
Assuming that exhaustive supramaxi-
mal blockade of AT1R provides an effi-
cient way to effectively silence the receptor 
signaling, Chen et al.2 treated SHRs with 
either a high or an ultrahigh dose of Cand 
to discern AT1R-independent effects. Both 
doses totally blocked AT1R, as was demon-
strated by the failure of exogenous infusion 
of Ang II to induce systemic and renal 
hemodynamic changes in SHRs. Despite 
this, the ultrahigh dose of Cand showed 
a greater effect than the high dose in sup-
pressing tubular NF-κB activation, chem-
okine (MCP-1 and RANTES) expression, 
and renal interstitial inflammation, as doc-
umented by reduction in ED1+ infiltrates, 
suggesting a superior renoprotective action 
independent of AT1R. Consistent with in 
vitro studies, Cand improved renal redox 
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status and, importantly, at an ultrahigh 
dose, increased GSH and GSH/GSSG ratio 
to values comparable to those estimated in 
normotensive WKY rats. A greater increase 
in GSH/GSSG ratio also significantly cor-
related with a greater reduction in NF-κB 
activation and interstitial infiltrates.2
Normalization of redox state by an ultra-
high dose of Cand is particularly relevant 
if we consider that, as opposed to normo-
tensive WKY rats, SHRs fail to upregulate 
the antioxidant defense as a compensatory 
mechanism to increased oxidative stress.
In line with the data of Chen et al.,2 pre-
vious studies have documented infiltra-
tion of inflammatory lymphocytes and 
macrophages into the renal parenchyma 
of SHRs that can be reduced by the anti-
oxidant melatonin.9 This treatment also 
improved hypertension. It is likely that 
inflammatory cells present in the intersti-
tium contribute to hypertension in SHRs 
by promoting local Ang II production and 
oxidative stress.
The anti-inflammatory effect of Cand 
has been previously investigated in SHRs 
in relation to hypertension-induced 
atherosclerosis in this model. Cand was 
shown to reduce the expression of vascular 
inflammatory cytokines to a greater extent 
than hypertensive triple therapy (hydrala-
zine, hydrochlorothiazide, and reserpine) 
despite comparable blood pressure con-
trol.12 Consistently, only Cand downregu-
lated NF-κB p50 subunit precursor p105, 
suggesting that the anti-inflammatory 
effect of Cand is beyond blood pressure 
reduction and that AT1R partly contrib-
utes to NF-κB activation at least in blood 
vessels. In light of the paper by Chen et al.,2 
one may expect superior protective effects 
of ultrahigh dosage of Cand on vascular 
disease, independently of AT1R.
In patients with chronic kidney disease, 
a double-blind, randomized, prospective 
study has recently documented an addi-
tional antiproteinuric effect of an ultrahigh 
dose of Cand compared with a standard 
dose.13 Whether the antiproteinuric effect 
translates into a slower rate of renal and 
cardiovascular end points has not been 
studied but can be speculated.
In the meantime, further experiments 
should prove the real benefit of ultrahigh 
dosage of Cand in comparison with stand-
ard dosage of Cand used alone or combined 
with an ACE inhibitor for chronic renal 
inflammation. This would support the 
rationale to test ultrahigh dosage of Cand, 
possibly targeted to oxidative stress, in the 
context of multiple drug treatment to induce 
remission of chronic kidney disease.
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The importance of patient 
education in the treatment  
of chronic kidney disease
Chester Fox1 and Linda S. Kohn
The article by Finkelstein and colleagues is a seminal work in helping us 
to understand the educational needs of pre–end-stage renal disease 
(pre-ESRD) patients. There are currently major deficits in patients’ 
perceived knowledge of their options for ESRD care. The Canadian 
system, with its more integrated and multidisciplinary approach to care, 
does a better job of communicating these options to patients. African 
Americans are less likely to be aware of their options. 
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In this issue of Kidney International, 
Finkelstein and colleagues1 point out 
that patients’ perceived knowledge of their 
options for treatment in end-stage renal 
disease (ESRD) is limited. The authors 
also note that patient choice is the major 
factor in choosing a dialysis therapy as 
patients approach ESRD. Thus, patients’ 
perceived lack of knowledge can have a 
major impact on treatment. This work is 
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